Bifogade filer
Alzinova appoints Tord Labuda as CEO
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Alzinova AB (publ) (ticker: ALZ), a Swedish biopharma company focused on the development of treatments for Alzheimer's disease, hereby announces that the board has appointed Tord Labuda as the new CEO of the company as of October 1, 2024.
Dr. Tord Labuda, M.Sci., PhD, has over 15 years of experience in senior positions in the pharmaceutical industry, more specifically in therapeutic areas with a strong emphasis on inflammation and immunology. Labuda's experience spans the entire value chain, from early discovery to regulatory approval and product launch.
Tord Labuda worked between 2008-2023 in internationally leading roles in LEO Pharma, where he most recently worked as Vice President & Head Global Clinical Development. Previous experiences within LEO Pharma include, among other things, that Labuda was President and Japan Representative Director, Vice President R&D Asia-Pacific and as Vice President R&D and Medical Affairs.
Tord most recently came from a role as a senior consultant in the biotechnology, medical technology and pharmaceutical sector. Tord Labuda is also a board member of the listed company NanoEcho AB (publ).
"We are very happy to welcome Tord Labuda into Alzinova's operations. Tord, with his extensive and broad experience from the industry and internationally, will be a very important piece of the puzzle during this exciting stage in our development. We are excited about Alzinova's potential and look forward to, together with our new CEO, driving the business forward at a continued rapid pace. At the same time, I want to take the opportunity to thank Carol Routledge, who handled the role of acting CEO in a good way during a busy period," says Julian Aleksov, chairman of the board of Alzinova AB.
"I am very happy to join Alzinova and look forward to becoming part of a dynamic team and a company with an extremely exciting and great potential. With my broad experience and deep understanding of the industry, I feel well equipped and extremely motivated to contribute to the company's continued development. Alzinova's innovative pipeline has the potential to change millions of lives, and I am committed to leading the team towards realizing this vision. Together, we can take significant steps forward in the fight against one of the most widespread neurological diseases of our time," says Tord Labuda, incoming CEO of Alzinova AB.
For additional information, please contact:
Chairman of the Board Julian Aleksov
E-mail: julian.aleksov@alzinova.com
About Alzinova
Alzinova AB is a Swedish clinical-stage biopharma company specializing in the treatment of Alzheimer’s disease targeting toxic amyloid beta oligomers. The lead candidate, ALZ-101, is being developed as a therapeutic vaccine for the treatment of Alzheimer's. Alzinova’s proprietary AβCC peptide™ technology enables the development of disease-modifying treatments that target the toxic amyloid beta oligomers involved in the onset and progression of the disease with high precision. Alzheimer’s is one of the most common and devastating neurological diseases globally, with of the order of 40 million people afflicted today. In addition, the antibody ALZ-201 is in preclinical development, and the ambition is to expand the pipeline further. The company’s Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com